» Articles » PMID: 38397970

Altered Expression of Intestinal Tight Junctions in Patients with Chronic Kidney Disease: A Pathogenetic Mechanism of Intestinal Hyperpermeability

Abstract

Background: Systemic inflammation in chronic kidney disease (CKD) is associated (as a cause or effect) with intestinal barrier dysfunction and increased gut permeability, with mechanisms not yet fully understood. This study investigated different parameters of the intestinal barrier in CKD patients, especially tight junction (TJ) proteins and their possible association with systemic endotoxemia and inflammation.

Methods: Thirty-three patients with stage I-IV CKD (n = 17) or end-stage kidney disease (ESKD) (n = 16) and 11 healthy controls underwent duodenal biopsy. Samples were examined histologically, the presence of CD3+ T-lymphocytes and the expression of occludin and claudin-1 in the intestinal epithelium was evaluated by means of immunohistochemistry, circulating endotoxin concentrations were determined by means of ELISA and the concentrations of the cytokines IL-1β, IL-6, IL-8, IL-10 and TNF-α in serum were measured using flow cytometry.

Results: Patients with stage I-IV CKD or ESKD had significantly higher serum endotoxin, IL-6, IL-8 and IL-10 levels compared to controls. Intestinal occludin and claudin-1 were significantly decreased, and their expression was inversely correlated with systemic endotoxemia. Regarding occludin, a specific expression pattern was observed, with a gradually increasing loss of its expression from the crypt to the tip of the villi.

Conclusion: The expression of occludin and claudin-1 in enterocytes is significantly reduced in patients with CKD, contributing to systemic endotoxemia and inflammatory responses in these patients.

Citing Articles

New insights into the intestinal barrier through "gut-organ" axes and a glimpse of the microgravity's effects on intestinal barrier.

Nie H, Ge J, Huang G, Liu K, Yue Y, Li H Front Physiol. 2024; 15:1465649.

PMID: 39450142 PMC: 11499591. DOI: 10.3389/fphys.2024.1465649.


Revitalizing the Gut Microbiome in Chronic Kidney Disease: A Comprehensive Exploration of the Therapeutic Potential of Physical Activity.

Vandecruys M, De Smet S, De Beir J, Renier M, Leunis S, Van Criekinge H Toxins (Basel). 2024; 16(6).

PMID: 38922137 PMC: 11209503. DOI: 10.3390/toxins16060242.

References
1.
You S, Ma Y, Yan B, Pei W, Wu Q, Ding C . The promotion mechanism of prebiotics for probiotics: A review. Front Nutr. 2022; 9:1000517. PMC: 9581195. DOI: 10.3389/fnut.2022.1000517. View

2.
Akchurin O, Kaskel F . Update on inflammation in chronic kidney disease. Blood Purif. 2015; 39(1-3):84-92. DOI: 10.1159/000368940. View

3.
Vaziri N, Yuan J, Norris K . Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol. 2012; 37(1):1-6. PMC: 3686571. DOI: 10.1159/000345969. View

4.
Madara J . Warner-Lambert/Parke-Davis Award lecture. Pathobiology of the intestinal epithelial barrier. Am J Pathol. 1990; 137(6):1273-81. PMC: 1877712. View

5.
Rahbar Saadat Y, Niknafs B, Hosseiniyan Khatibi S, Ardalan M, Majdi H, Bahmanpoor Z . Gut microbiota; an overlooked effect of phosphate binders. Eur J Pharmacol. 2019; 868:172892. DOI: 10.1016/j.ejphar.2019.172892. View